Literature DB >> 29964279

Diagnosing the Treatment.

Sarah A McGuffin1,2, Robert L Trowbridge3,4, Ann M O'Hare5,6, Andrew P Olson7,8,9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29964279      PMCID： PMC6467279          DOI： 10.12788/jhm.2981

Source DB:  PubMed          Journal:  J Hosp Med        ISSN： 1553-5592            Impact factor:   2.960


× No keyword cloud information.
  20 in total

Review 1.  Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer.

Authors:  Richard J Sylvester
Journal:  Int J Urol       Date:  2010-11-22       Impact factor: 3.369

2.  Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy.

Authors:  Omar Y Gonzalez; Daniel M Musher; Indira Brar; Seth Furgeson; Maha R Boktour; Edward J Septimus; Richard J Hamill; Edward A Graviss
Journal:  Clin Infect Dis       Date:  2003-01-03       Impact factor: 9.079

3.  Systemic Bacillus Calmette-Guerin sepsis manifesting as hypercalcaemia and thrombocytopenia as a complication of intravesical Bacillus Calmette-Guerin therapy.

Authors:  N Nayar; K Briscoe
Journal:  Intern Med J       Date:  2015-10       Impact factor: 2.048

4.  In vivo activity of released cell wall lipids of Mycobacterium bovis bacillus Calmette-Guérin is due principally to trehalose mycolates.

Authors:  Rachel E Geisel; Kaori Sakamoto; David G Russell; Elizabeth R Rhoades
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

Review 5.  Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.

Authors:  Peter J Tebben; Ravinder J Singh; Rajiv Kumar
Journal:  Endocr Rev       Date:  2016-09-02       Impact factor: 19.871

Review 6.  Hypercalcemia in granulomatous disorders: a clinical review.

Authors:  O P Sharma
Journal:  Curr Opin Pulm Med       Date:  2000-09       Impact factor: 3.155

7.  NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.

Authors:  Peter E Clark; Philippe E Spiess; Neeraj Agarwal; Rick Bangs; Stephen A Boorjian; Mark K Buyyounouski; Jason A Efstathiou; Thomas W Flaig; Terence Friedlander; Richard E Greenberg; Khurshid A Guru; Noah Hahn; Harry W Herr; Christopher Hoimes; Brant A Inman; A Karim Kader; Adam S Kibel; Timothy M Kuzel; Subodh M Lele; Joshua J Meeks; Jeff Michalski; Jeffrey S Montgomery; Lance C Pagliaro; Sumanta K Pal; Anthony Patterson; Daniel Petrylak; Elizabeth R Plimack; Kamal S Pohar; Michael P Porter; Wade J Sexton; Arlene O Siefker-Radtke; Guru Sonpavde; Jonathan Tward; Geoffrey Wile; Mary A Dwyer; Courtney Smith
Journal:  J Natl Compr Canc Netw       Date:  2016-10       Impact factor: 11.908

8.  Four cases of disseminated Mycobacterium bovis infection following intravesical BCG instillation for treatment of bladder carcinoma.

Authors:  Krisztina A Nadasy; Rikin S Patel; Michael Emmett; Ricardo A Murillo; Marc A Tribble; Robert D Black; William L Sutker
Journal:  South Med J       Date:  2008-01       Impact factor: 0.954

9.  Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG.

Authors:  Maurizio Brausi; Jorg Oddens; Richard Sylvester; Aldo Bono; Cees van de Beek; George van Andel; Paolo Gontero; Levent Turkeri; Sandrine Marreaud; Sandra Collette; Willem Oosterlinck
Journal:  Eur Urol       Date:  2013-07-24       Impact factor: 20.096

Review 10.  Managing the adverse events of intravesical bacillus Calmette-Guérin therapy.

Authors:  Karel Decaestecker; Willem Oosterlinck
Journal:  Res Rep Urol       Date:  2015-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.